Pharma has been slow – painfully slow – to adopt mobile marketing strategies and tactics.
Teva Pharmaceutical Industries Ltd. said its experimental drug to prevent migraines cleared another late-stage study.
Novartis touted new data from its T-cell therapy CTL019, saying it is on a par with results of experimental molecules from Kite Pharma and Juno Therapeutics that also target aggressive blood cancers.
AbbVie’s rheumatoid arthritis drug was superior to a placebo in a late-stage study involving patients that have not responded adequately to standard treatments.
Promising new data on blood and bone marrow cancer therapies that re-engineer immune system cells are convincing more doctors of the validity of the approach, according to Reuters interviews at the world’s biggest annual oncology meeting.
In the eyes of investors, Bristol-Myers Squibb has not really recovered from bad news in August 2016 of its clinical trial of Opdivo (nivolumab) as monotherapy in non-small cell lung cancer. Although the company had quite a bit of good news at the June 2017 ASCO meeting, investors still seem leery.
Roche’s seven-year-old rheumatoid arthritis drug Actemra is being linked to hundreds of deaths due to undisclosed side effects.
AstraZeneca continued its program of divesting old medicines with the sale for up to $302 million of migraine drug Zomig to Germany’s Grunenthal.
Intouch Solutions proudly announces the promotions of both Vicky Cory and Krisha Newham to vice president of client services.
For patients with deadly and debilitating conditions, FDA drug approvals can be cause for celebration. Many of these patients and their families have been waiting years for better therapies – or any therapy at all. They consume every public announcement about drug approvals for their particular disease like it’s water in the desert. But there is also a sense of trepidation once the drug launches. How much will this new drug cost? What will insurance cover? What will be our share?